secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0000950170-24-102561
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences receives $9.75M cash + $3.25M Imugene shares from convertible note maturity
--------------------------------------------------------------------------------

- Convertible note from August 2023 azer-cel deal with Imugene matured; Precision receives $9.75M cash and $3.25M in Imugene ordinary shares.
- Cash injection extends expected runway into second half of 2026; Q2 2024 cash balance was ~$123.6M before this receipt.
- Company on track to file applications for PBGENE-HBV (chronic hepatitis B) with multiple global regulators later in 2024.
- Precision expects to generate Phase 1 clinical data across multiple in vivo gene editing programs starting first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024102561/0000950170-24-102561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024102561/dtil-20240903.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-102561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer